NORDSIEK MICHAEL T.,LEVY SHARON F.,LEE JAMES H.,KULP JAMES H.,BALAJI KODUMUDI S.,MENG TZE-CHIANG,WU JASON J.,BAHM VALYN S.,BABILON ROBERT
申请号：
PL10800190
公开号：
PL2453747T3
申请日:
2010.04.30
申请国别(地区):
PL
年份:
2018
代理人:
摘要：
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (&ldquo；FDA&rdquo；), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (&ldquo；FDA&rdquo；) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
